Clinical Trial Update: A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes [Phase 2]

View source ↗

Summary

Phase 2 trial of pracinostat with azacitidine in high-risk myelodysplastic syndromes terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Pracinostat (pracinostat)

Snippet

Sponsor: Helsinn Healthcare SA | Conditions: Myelodysplastic Syndromes | Phase 2 | Status: TERMINATED | Results posted: 2022-03-02